Is Denali Therapeutics Inc. (DNLI)’s Fuel For Real? The Stock Just Increased Again

March 14, 2018 - By marketbeat

The stock of Denali Therapeutics Inc. (NASDAQ:DNLI) is a huge mover today! The stock increased 8.80% or $1.77 during the last trading session, reaching $21.89. About 367,066 shares traded or 11.57% up from the average. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 9 months positive chart setup for the $1.97 billion company. It was reported on Mar, 14 by We have $23.64 PT which if reached, will make NASDAQ:DNLI worth $157.68M more.

More notable recent Denali Therapeutics Inc. (NASDAQ:DNLI) news were published by: which released: “Why this $300 million biotech IPO could be huge — or another flop in …” on December 07, 2017, also with their article: “VC-backed Denali Therapeutics goes public” published on December 08, 2017, published: “The Funded: Denali Therapeutics sets IPO price range; 4 others raise rounds” on November 29, 2017. More interesting news about Denali Therapeutics Inc. (NASDAQ:DNLI) were released by: and their article: “Denali Therapeutics Files To Raise $100 Million IPO” published on November 17, 2017 as well as‘s news article titled: “Takeda and Denali team up in neurodegenerative diseases” with publication date: January 05, 2018.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $1.97 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: